News >

Novel Agents, Combos Transforming Treatment in MCL and CLL

Jessica Hergert
Published: Monday, Oct 14, 2019

James N. Gerson, MD, assistant professor of clinical medicine, Perelman School of Medicine, University of Pennsylvania

James N. Gerson, MD

The introduction of the novel targeted agents ibrutinib (Imbruvica), acalabrutinib (Calquence), and venetoclax (Venclexta), among others, is rapidly changing the relapsed/refractory space of mantle cell lymphoma (MCL) and the upfront setting of chronic lymphocytic leukemia (CLL), said James N. Gerson, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication